ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1744

Preceding Mental Health Diagnosis Does Predict Eventual Neuropsychiatric Disease in Childhood-Onset Systemic Lupus Erythematosus

Ekemini Ogbu1, Clare Treutel1, Angela Merritt2, Michael Wagner1 and Hermine Brunner1, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Cincinnati Childrens Hospital Medical Center, Cincinnati, OH

Meeting: ACR Convergence 2025

Keywords: neuropsychiatric disorders, Pediatric rheumatology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: Abstracts: Pediatric Rheumatology – Clinical II (1740–1745)

Session Type: Abstract Session

Session Time: 11:00AM-11:15AM

Background/Purpose: Childhood-onset Systemic Lupus Erythematosus (cSLE) affects approximately 1 in 10,000 children in the United States, with the estimated prevalence of childhood neuropsychiatric SLE (NPSLE) at 43 – 95%. Risk factors of NPSLE are poorly understood though NPSLE could severely impact cognitive development and long-term neurologic outcomes. Thus, identification of accurate predictors of increased NPSLE risk are greatly needed. The objective of our study was to understand whether premorbid mental health history predicted neuropsychiatric disease in cSLE. We hypothesized that mental health diagnoses and prescriptions occurring before cSLE diagnosis are predictive of future NPSLE.

Methods: Retrospective case-control study using a federated patient database (TriNetX Research network). We included patients aged ≤18 years at first SLE diagnosis between January 2014 and April 2025. We defined NPSLE using the 19 American College of Rheumatology classified neuropsychiatric syndromes with corresponding ICD-10 codes. Premorbid mental health diagnosis was defined as a neuropsychiatric diagnosis any time up to one day before initial SLE diagnosis using specific ICD-10 codes [(i.e. mood disorders (F30 – 39), depression (F32), anxiety disorders (F40 – 48; F41, F41.1, F41.9), adjustment disorders (F43.2) and attention deficit hyperactivity disorder (F90)]; and prescriptions using Veterans Affairs National Drug File (VA NDF) codes (CN300, CN301, CN302, CN309, CN400, CN600, CN601, CN609). The risk of NPSLE occurrence in relation to premorbid mental health diagnosis or prescription was analyzed over 2 time periods:(a)18-months and (b) total observation period, prior to SLE diagnosis. Propensity score matching was based on patient sex and race, and regression analyses conducted for the risk of NPSLE compared between cases and controls.

Results: The total TriNetX population queried included approximately 140 million patients from 102 healthcare organizations . A total of 8504 cSLE patients (5,880 cSLE patients with NPSLE and 2,624 without NPSLE) were identified. After propensity matching by sex, ethnicity, and race, 2,313 patients were included in each cohort (Table 1). Premorbid diagnosis of mood disorders, depression and anxiety disorders within 18 months prior to cSLE diagnosis were associated with > 2-fold risk of subsequent NPSLE (RR: 3.4, 3.6, 3.0; all p < 0.05. Similarly, the risk of developing NPSLE was increased with a diagnosis of mood disorders, depression, anxiety and attention-deficit hyperactivity disorder at any time point prior to cSLE diagnosis (RR: 2.9, 3.0, 3.0,2.1; all p < 0.05). History of use of anticonvulsant, antidepressants and sedatives within 18 months or at any time prior to cSLE diagnosis was also associated with increased risk of subsequent NPSLE. (Figures 1 & 2).

Conclusion: Preceding mental health diagnoses predict future neuropsychiatric disease in cSLE. Further research is needed to understand earlier clinical, laboratory and neuroimaging indicators of NPSLE development to delineate surveillance measures and interventions.

Supporting image 1

Supporting image 2Figure 1: Risk of NPSLE occurrence in relation to premorbid mental health diagnosis or prescription any time prior to cSLE diagnosis

Supporting image 3Figure 2: Risk of NPSLE occurrence in relation to premorbid mental health diagnosis or prescription within 18 months prior to cSLE diagnosis.


Disclosures: E. Ogbu: Cartesian Therapeutics, 2; C. Treutel: None; A. Merritt: None; M. Wagner: None; H. Brunner: AbbVie, 2, AstraZeneca-Medimmune, 2, Biogen, 2, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, Eli Lilly, 2, EMD Serono, 2, F. Hoffmann-La Roche, 2, Genentech, 5, GlaxoSmithKline, 2, Merck, 2, Novartis, 2, Pfizer, 2, 5, Sanofi, 2, UCB, 2.

To cite this abstract in AMA style:

Ogbu E, Treutel C, Merritt A, Wagner M, Brunner H. Preceding Mental Health Diagnosis Does Predict Eventual Neuropsychiatric Disease in Childhood-Onset Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/preceding-mental-health-diagnosis-does-predict-eventual-neuropsychiatric-disease-in-childhood-onset-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/preceding-mental-health-diagnosis-does-predict-eventual-neuropsychiatric-disease-in-childhood-onset-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology